This study is a multicenter, open phase I clinical study of dose escalation, cohort expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CSCJC3456 in patients with advanced malignant solid tumors.
Voluntarily sign the informed consent form and follow protocol requirements;
Aged 18 to 75 (both inclusive), male or female, regardless of race;
Expected survival period ≥ 12 weeks;
ECOG PS score ≤1;
Radically cured basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, cervical carcinoma in situ, or breast cancer in situ;
Second primary cancer that has been cured with no recurrence within 5 years;
Patients who are allergic to any component of the study drug or have a history of severe allergies;
Major surgery or major trauma occurred within 4 weeks before the first study drug, but diagnostic tissue biopsies are allowed. Severe trauma refers to unhealed wounds, ulcers, or fractures;